GLP2-T

GLP2-T (tirzepatide) is a dual GLP-1 / GIP receptor agonist: a 39-amino-acid synthetic peptide based on the native GIP sequence, modified with a C20 fatty diacid chain that binds albumin and extends the half-life to approximately 5 days, enabling once-weekly subcutaneous dosing.

It holds FDA approval under two labels from Eli Lilly — Mounjaro for type 2 diabetes, Zepbound for chronic weight management in adults with obesity or overweight with at least one weight-related condition, and for moderate-to-severe obstructive sleep apnoea in adults with obesity. Same molecule, different labels and insurance pathways.

The dual receptor activation is the point of difference. Prior incretin agents targeted GLP-1 alone. The original hypothesis was that GIP antagonism would aid weight loss; the clinical data inverted that, and GIP agonism layered onto GLP-1 agonism outperforms GLP-1 alone. Comparative efficacy: 20.2% against 13.7% for GLP1-S over 72 weeks in SURMOUNT-5, with waist circumference reduction of 18.4 cm against 13.0 cm; earlier figures put the margin at 5–7%. Against the triple agonist GLP3-R, near-equivalent total weight loss but over 72 weeks versus 48.

Documented drug interactions: oral contraceptives, where peak ethinyl oestradiol exposure fell 59% and overall exposure 20%, prompting a manufacturer recommendation of a non-oral method or backup barrier for 4 weeks after initiation and after each escalation — an interaction specific to GLP2-T and not seen with GLP-1-only agents; insulin and sulfonylureas, which may need substantial dose reduction to prevent hypoglycaemia; oral medications generally, whose absorption is affected by delayed gastric emptying. Alcohol raises hypoglycaemia risk and worsens nausea and dehydration; dehydration itself drives the renal risk and is amplified by concurrent ACE inhibitors, diuretics, ARBs, and heart failure regimens. Berberine and metformin, chromium and other insulin sensitisers, each add hypoglycaemia risk. Large, greasy meals raise the likelihood of nausea.

Peptide interactions graded severe: other GLP peptides, on receptor redundancy and desensitisation; tesamorelin, on elevated glucose; and IGF-1 LR3 / DES with strong ghrelin agonists such as GHRP-2 and GHRP-6. Graded moderate: IGF-1 LR3 and IGF-1 DES for hypoglycaemia; CJC-1295 with DAC, which blunts the metabolic benefit; GHRP-2, GHRP-6 and hexarelin, which counter appetite suppression; BAM-15; LL-37; and oxytocin. Research on MASH, HFpEF, and further metabolic indications is expanding.

GLP2-T activates two incretin receptors simultaneously, and the arms are additive rather than redundant.

GLP-1 receptor activation. Glucose-dependent insulin secretion from the pancreas, delayed gastric emptying with prolonged satiety, reduced hepatic glucose output, and central action reducing appetite and the reward valuation of food. This is the axis GLP1-S targets; appetite suppression and delayed gastric emptying are the primary weight-loss drivers because they make a sustained caloric deficit tractable.

GIP receptor activation. GLP2-T has binding affinity at the GIP receptor comparable to native GIP and is approximately five times more potent there. Consequences: improved post-prandial insulin secretion as the pancreas becomes more responsive to rising glucose, flatter glycaemic excursions, and improved nutrient partitioning, with adipose and muscle taking up and using substrate more efficiently rather than leaving glucose and lipid circulating. GIP signalling also appears to influence adipose tissue metabolism and may underlie the improved tolerability relative to pure GLP-1 agents.

Biased agonism. GLP2-T is an imbalanced and biased dual agonist (Willard et al., 2020). At the GLP-1 receptor it favours cAMP signalling over beta-arrestin recruitment. Strong insulinotropic output is preserved without proportionate receptor internalisation — the process by which the receptor is drawn into the cell and becomes temporarily unavailable — so efficacy at the GLP-1 receptor is maintained while gastrointestinal effects driven by excessive receptor activation are potentially reduced.

Combined effect. Appetite suppression exceeds either pathway alone, glycaemic handling improves, and body composition analyses indicate a higher proportion of lean mass is preserved during weight loss than with GLP-1-only agents, plausibly via GIP-mediated nutrient partitioning.

Metabolic cascade. Adiposity, particularly visceral adiposity, drives insulin resistance, which in turn drives hypertension, dyslipidaemia, hepatic steatosis, and ultimately type 2 diabetes and cardiovascular disease. Reducing fat mass and improving insulin and nutrient handling improves the entire cascade — blood pressure, lipids, liver function, and long-term cardiovascular risk sit underneath the scale weight. Energy balance is supported in part through hypothalamic GIP receptors.

Body composition. SURMOUNT-1, 72 weeks: 15.0% (5 mg), 19.5% (10 mg), 20.9% treatment-regimen to 22.5% efficacy estimand (15 mg) versus 3.1% placebo; 91% at 15 mg lost at least 5%, over half lost 20% or more, more than a third lost 25% or more. A 24.7% average total body weight loss at 72 weeks has also been reported. SURMOUNT-4: 25.3% total reduction at 88 weeks on continued treatment. DEXA substudy (Look et al., 2025): 21.3% body weight reduction, 33.9% fat mass loss, 10.9% lean mass loss — approximately 75% fat and 25% lean, matching the placebo ratio.

Appetite. Reduced appetite and cravings, enhanced satiety, and improved energy balance via hypothalamic GIP signalling.

Metabolic. Supports fat oxidation and metabolic rate; improved nutrient partitioning.

Glycaemic. Improved insulin sensitivity and glucose control; HbA1c reduced by up to 2.3 percentage points in the SURPASS programme, with statistical superiority to semaglutide 1 mg at all dose levels in SURPASS-2.

Cardiometabolic. Systolic blood pressure down approximately 4.8 mmHg, diastolic approximately 1.7 mmHg; reduced LDL, triglycerides down up to 22.5%, increased HDL. SURPASS-CVOT: noninferior to dulaglutide for MACE over a median 4-year follow-up (12.2% versus 13.1%), with a trend toward superiority that did not reach significance.

Hepatic. SYNERGY-NASH: MASH resolution without worsening fibrosis in 44%, 56%, and 62% at 5, 10, and 15 mg against 10% placebo at 52 weeks; at least one stage of fibrosis improvement in roughly half of treated participants.

Respiratory. SURMOUNT-OSA: apnoea-hypopnoea index reduced by up to 62.8% over 52 weeks, with approximately 50% achieving OSA resolution; hsCRP and blood pressure also improved.

Endocrine. ENDO 2025 data: increased free and total testosterone in men with obesity and metabolic hypogonadism, with one Italian study reporting greater gains at 2 months than transdermal testosterone replacement alone — consistent with reduced aromatase activity as adipose mass falls.

Trial trajectory. In SURMOUNT-1 the majority of weight loss occurred within the first 40 weeks, with the rate attenuating as participants approached a new equilibrium; some were still declining at week 72, particularly at higher doses. The titration phase — the first 4 to 20 weeks depending on target dose — is an adaptation window rather than the main efficacy window; the bulk of the result accrues after reaching and holding a maintenance dose.

SURMOUNT-4 extension: 25.3% total weight reduction at 88 weeks on continued treatment; 14.0% regain in those switched to placebo; 89.5% of continuers maintained at least 80% of weight lost, against 16.6% on placebo.

Reported timelines. The following is aggregated from user reports and is not published data.

Weeks 1 to 4 (2.5 mg): mild to moderate appetite suppression begins; nausea common, heaviest in week one; reported loss ranges from negligible to 5 to 10 pounds, largely water and reduced food volume.

Weeks 5 to 12 (5 to 7.5 mg): appetite suppression more pronounced, consistent weekly loss of 1 to 3 pounds, marked reduction in food noise, side effects stabilising.

Weeks 13 to 24 (7.5 to 15 mg): peak effect window; most visible rate of loss; energy improves as metabolic parameters shift, glycaemia stabilises, lipids begin moving.

Weeks 24 to 72 (maintenance): rate of loss slows as equilibrium approaches. This is expected. Escalating dose in response to the slowdown chases a number rather than a result; metabolic improvement continues after the scale plateaus.

Reported outcomes. Users describe results consistent with trial data when nutrition and training are in place — commonly 15 to 25 pounds in the first 3 months and 40 to 60 pounds over 6 to 12 months. Those prioritising protein and resistance training consistently report better body composition than those relying on appetite suppression alone. Plateaus after the first 6 months are frequently traced to insufficient protein, inadequate resistance training, or a dose that has stopped suppressing appetite effectively. Insomnia attributed to the drug is typically traced to undereating: sharply reduced intake, overnight glucose decline, compensatory cortisol, and a 2 AM waking. Eating more across the day and a protein-containing snack before bed usually resolves it.

Discontinuation. 82.5% of those who stopped in SURMOUNT-4 regained at least 25% of lost weight within one year.

Studied doses: 5 mg, 10 mg, and 15 mg weekly across the SURMOUNT and SURPASS programmes, with trial titration starting at 2.5 mg and escalating by 2.5 mg every 4 weeks. Efficacy is dose-dependent with diminishing returns — 5 mg to 10 mg added roughly 4.5 percentage points of weight loss, 10 mg to 15 mg roughly 3 more.

The standard ladder matches FDA labelling and trial design: 2.5 mg for weeks 1 to 4, 5 mg weeks 5 to 8, 7.5 mg weeks 9 to 12, 10 mg weeks 13 to 16, 12.5 mg weeks 17 to 20, 15 mg from week 21 as the maximum. Escalation exists to offset adaptation, not to chase a larger number; total time on drug drives the outcome. The 2.5 mg lead-in is not skippable. Earlier guidance permitted a 5 mg start for users with at least one month of prior GLP exposure at the standard starter dose, regardless of elapsed time since.

Maintenance dose selection is a three-part assessment at each step: rate of loss, tolerability, and adequacy of appetite suppression. Loss of 1 to 2 pounds per week with tolerable side effects is a reasonable stopping point — minimum effective dose rather than maximum tolerated. Where side effects are difficult: extend time at the current dose, step back to the last stable dose and retry later, or escalate in a smaller increment if the preparation allows.

Route and timing: subcutaneous, once weekly, fixed day. Abdomen, thigh, or upper arm, rotating sites. Any time of day; fasting not required.

Reconstitution: vial sizes of 5 mg or 10 mg vary by supplier, with bacteriostatic water volume per supplier documentation. Refrigerate after reconstitution. Previously documented concentrations were 10 mg in 0.5 mL and 30 mg in 1.5 mL, both giving 20 mg/mL, and 60 mg in 2.5 mL giving 24 mg/mL.

Foundations: protein at one gram per pound of goal body weight daily, tracked with the same rigour as the dose; resistance training a minimum of 2 to 3 times weekly as the only stimulus preserving lean mass in a deficit; 7 to 9 hours of sleep; daily walking for expenditure without recovery cost.

Monitoring: fasting glucose and HbA1c, lipid panel, liver function, renal function where GI symptoms cause dehydration, testosterone in men, and body composition rather than scale weight alone. Disclose use before any procedure under anaesthesia — delayed gastric emptying is the aspiration mechanism. The interaction list is the practical constraint on stacking; the severe-grade entries are other GLP peptides, tesamorelin, and IGF-1 LR3 / DES with strong ghrelin agonists.

SURMOUNT-1 (Jastreboff et al., 2022): RCT, 2,539 adults with obesity without diabetes, 5/10/15 mg versus placebo for 72 weeks. Dose-dependent loss of 15.0%, 19.5% and 20.9% (treatment-regimen estimand; 22.5% by efficacy estimand at 15 mg) versus 3.1%. 36% of the 15 mg arm lost 25% or more. All prespecified cardiometabolic endpoints improved. Adverse events predominantly gastrointestinal and concentrated in escalation. Limitations: 72-week duration, predominantly white female population.

SURMOUNT-4 (Aronne et al., 2024, JAMA): 670 adults randomised after a 36-week lead-in producing 20.9% loss. Continuation reached 25.3% total reduction at 88 weeks; placebo switch regained 14.0% of body weight; 89.5% of continuers retained at least 80% of loss versus 16.6%. Population enriched for responders.

SURMOUNT-5 (Aronne et al., 2025): 751 adults, maximum tolerated tirzepatide (10 or 15 mg) versus semaglutide (1.7 or 2.4 mg), 72 weeks. 20.2% versus 13.7% weight loss; waist 18.4 cm versus 13.0 cm; GI discontinuation 2.7% versus 5.6%. Open-label dose selection within arms.

SURPASS-2 (Frias et al., 2021): 1,879 patients with Type-2 diabetes, 40 weeks against semaglutide 1 mg. Non-inferior and superior on HbA1c at all doses, greater weight loss at all doses. Comparator dose was 1 mg, not 2.4 mg. Across SURPASS, HbA1c fell by up to 2.3 percentage points.

SURPASS-CVOT (2025): 13,165 patients with Type-2 diabetes and atherosclerotic disease versus dulaglutide, median 4-year follow-up. MACE 12.2% versus 13.1% — non-inferiority met (P = 0.003), superiority not (P = 0.09). Active comparator, so no placebo-controlled cardiovascular claim.

SURMOUNT-OSA (Malhotra et al., 2024): AHI reduced by up to 62.8% over 52 weeks, roughly 50% achieving OSA resolution, with blood pressure and hsCRP improvement.

SYNERGY-NASH (Loomba et al., 2024): 190 adults with biopsy-confirmed MASH; resolution without worsening fibrosis in 44%, 56% and 62% versus 10% placebo, with at least one-stage fibrosis improvement in roughly half. Phase 2, small.

Body composition post hoc (Look et al., 2025): 160 DEXA subjects, 21.3% weight reduction, 33.9% fat mass loss, 10.9% lean mass loss — about 75:25 fat to lean, matching the placebo ratio. Hidalgo Ramos et al. (2025), six RCTs, concluded fat mass reduction with relative preservation of lean mass.

Mechanistic basis: Willard et al. (2020) characterised the compound as an imbalanced, biased dual GIP and GLP-1 receptor agonist favouring cAMP signalling over beta-arrestin recruitment.